Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog. Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Vertex Pharmaceuticals beat expectations for revenue but missed on earnings. The company has two recent FDA approvals and several treatments in late-stage trials. The core CF treatments make up ...

After hours: February 13 at 6:00:01 PM EST Loading Chart for A ...

新浪财经免费提供股票、基金、债券、外汇等行情数据以及其他资料均来自相关合作方，仅作为用户获取信息之目的，并不构成投资建议。 新浪财经 ...